Cell therapeutic approaches to immunosuppression after clinical kidney transplantation
- PMID: 28229281
- DOI: 10.1007/s00467-017-3599-2
Cell therapeutic approaches to immunosuppression after clinical kidney transplantation
Abstract
Refinement of immunosuppressive strategies has led to further improvement of kidney graft survival in recent years. Currently, the main limitations to long-term graft survival are life-threatening side effects of immunosuppression and chronic allograft injury, emphasizing the need for innovative immunosuppressive regimens that resolve this therapeutic dilemma. Several cell therapeutic approaches to immunosuppression and donor-specific unresponsiveness have been tested in early phase I and phase II clinical trials in kidney transplantation. The aim of this overview is to summarize current cell therapeutic approaches to immunosuppression in clinical kidney transplantation with a focus on myeloid suppressor cell therapy by mitomycin C-induced cells (MICs). MICs show great promise as a therapeutic agent to achieve the rapid and durable establishment of donor-unresponsiveness in living-donor kidney transplantation. Cell-based therapeutic approaches may eventually revolutionize immunosuppression in kidney transplantation in the near future.
Keywords: Immunosuppression; Mitomycin C-induced cells; Myeloid suppressor cells; Regulatory T cells; Tolerance; Transplantation.
Similar articles
-
Cell therapy for immunosuppression after kidney transplantation.Langenbecks Arch Surg. 2015 Jul;400(5):541-50. doi: 10.1007/s00423-015-1313-z. Epub 2015 Jun 17. Langenbecks Arch Surg. 2015. PMID: 26077202 Review.
-
Mesenchymal stromal cells for tolerance induction in organ transplantation.Hum Immunol. 2018 May;79(5):304-313. doi: 10.1016/j.humimm.2017.12.008. Epub 2017 Dec 27. Hum Immunol. 2018. PMID: 29288697 Review.
-
The need for minimization strategies: current problems of immunosuppression.Transpl Int. 2015 Aug;28(8):891-900. doi: 10.1111/tri.12553. Epub 2015 Mar 18. Transpl Int. 2015. PMID: 25752992 Review.
-
An update on chemical pharmacotherapy options for the prevention of kidney transplant rejection with a focus on costimulation blockade.Expert Opin Pharmacother. 2017 Jun;18(8):799-807. doi: 10.1080/14656566.2017.1323876. Epub 2017 May 9. Expert Opin Pharmacother. 2017. PMID: 28460546 Review.
-
Generation of suppressive blood cells for control of allograft rejection.Clin Sci (Lond). 2015 May;128(9):593-607. doi: 10.1042/CS20140258. Clin Sci (Lond). 2015. PMID: 25495457
Cited by
-
Pre-transplant infusion of donor leukocytes treated with extracorporeal photochemotherapy induces immune hypo-responsiveness and long-term allograft survival in murine models.Sci Rep. 2022 May 4;12(1):7298. doi: 10.1038/s41598-022-11290-w. Sci Rep. 2022. PMID: 35508582 Free PMC article.
-
Phase I trial of donor-derived modified immune cell infusion in kidney transplantation.J Clin Invest. 2020 May 1;130(5):2364-2376. doi: 10.1172/JCI133595. J Clin Invest. 2020. PMID: 31990685 Free PMC article. Clinical Trial.
-
Individualised immunosuppression with intravenously administered donor-derived modified immune cells compared with standard of care in living donor kidney transplantation (TOL-2 Study): protocol for a multicentre, open-label, phase II, randomised controlled trial.BMJ Open. 2022 Nov 11;12(11):e066128. doi: 10.1136/bmjopen-2022-066128. BMJ Open. 2022. PMID: 36368749 Free PMC article.
-
Five-year follow-up of a phase I trial of donor-derived modified immune cell infusion in kidney transplantation.Front Immunol. 2023 Jul 11;14:1089664. doi: 10.3389/fimmu.2023.1089664. eCollection 2023. Front Immunol. 2023. PMID: 37483623 Free PMC article. Clinical Trial.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical